Krognes Steve E. sold $1.2M of GH
Krognes Steve E. sold 6,674 shares of Guardant Health, Inc. (GH) at an average of $175.74 ($174.46–$177.48, $1.17M total) across 4 trades on 2026-09-16.
How this was made
The 30-second read
Why it matters
The director's sale may be interpreted as a bearish cue, but the modest size limits market reaction.
Market read
Primary insider sale filing with modest dollar amount; limited immediate trading impact.
What to watch
Recent positive trial data or upcoming earnings could offset the impact of the sale.
Background
SEC Form 4 filings disclose insider transactions and are considered primary sources of material information.
Ticker impact
Director Steve Krognes sold 6,674 shares of Guardant Health for $1.17M on 2026-09-16.
Possible modest downside of 1‑2% in the next trading session.
A $1.2M sale by a director is material enough to attract attention, but the amount is modest relative to market cap.
Market effects
Limited impact on the broader biotech sector; insider sales are common and usually company‑specific.
No significant regional effect; the filing is U.S.‑focused.
Minimal global relevance beyond Guardant Health investors.
Counterpoint
The sale could be a routine portfolio rebalancing rather than a negative signal.
Key entities
- CompanyGuardant Health, Inc.
US‑listed liquid biopsy company (ticker GH).
- IndividualSteve E. Krognes
Director of Guardant Health who sold shares.
